A pharmacist furnishing an opioid antagonist for overdose
reversal pursuant to section 4052.01 of the Business and Professions Code shall
satisfy the requirements of this section.
(a) As used in this section:
(1) "Opioid" means naturally derived opiates
as well as synthetic and semi-synthetic opioids.
(2) "Recipient" means the person to whom an
opioid antagonist is furnished.
(b) Training. Prior to furnishing an opioid
antagonist, pharmacists who use this protocol must have successfully completed
a minimum of one hour of an approved continuing education program or equivalent
curriculum-based training program, completed in a Board recognized school of
pharmacy, specific to the use of opioid antagonists for overdose
reversal.
(c) Protocol for
Pharmacists Furnishing Opioid Antagonists. Before providing an opioid
antagonist, the pharmacist shall:
(1) Provide
the recipient training in opioid overdose prevention, recognition, response,
and administration of the opioid antagonist furnished.
(2) When an opioid antagonist is furnished:
(A) The pharmacist shall provide the
recipient with appropriate counseling and information on the product furnished,
including dosing, effectiveness, adverse effects, storage conditions,
shelf-life, and safety. The recipient is not permitted to waive the required
consultation.
(B) The pharmacist
shall provide the recipient with any informational resources on hand and/or
referrals to appropriate resources if the recipient indicates interest in
addiction treatment, recovery services, or medication disposal resources at
this time.
(C) The pharmacist shall
answer any questions the recipient may have regarding the opioid antagonist
furnished.
(3) Product
Selection: A pharmacist shall advise the recipient on how to choose the route
of administration based on the formulation available, how well it can likely be
administered, the setting, and local context. A pharmacist may also recommend
optional items when appropriate, including alcohol pads, rescue breathing
masks, and rubber gloves.
(4)
Labeling: A pharmacist shall label the opioid antagonist consistent with law
and regulations.
(5) Notifications:
At the request of the patient, a pharmacist shall notify the
identified primary care provider, if any, of the product furnished or enter
appropriate information in a shared patient record system as permitted by the
primary care provider. If the patient does not have or does not identify a
primary care provider, the pharmacist shall provide the patient a written
record of the drug furnished along with a recommendation for the patient to
consult with an appropriate health care provider of the patient's
choice.
Notes
Cal. Code Regs.
Tit. 16, §
1746.3
Note: Authority cited: Sections 4005 and 4052.01, Business
and Professions Code. Reference: Section 4052.01, Business and Professions
Code.
Note: Authority cited: Section
4052.01,
Business and Professions Code. Reference: Section
4052.01,
Business and Professions Code.
1.
New section filed 4-10-2015 as a deemed emergency exempt from OAL review
pursuant to Business and Professions Code section
4052.01(e);
operative 4-10-2015 (Register 2015, No. 15). A Certificate of Compliance must
be transmitted to OAL by 10-7-2015, pursuant to Business and Professions Code
section
4052.01(e),
or emergency language will be repealed by operation of law on the following
day.
2. New section refiled 9-29-2015 as a deemed emergency exempt
from OAL review pursuant to Business and Professions Code section
4052.01(e);
operative 10-8-2015 pursuant to Government Code section
11346.1(d)
(Register 2015, No. 40). A Certificate of Compliance must be transmitted to OAL
by 4-5-2016, pursuant to Business and Professions Code section
4052.01(e),
or emergency language will be repealed by operation of law on the following
day.
3. Certificate of Compliance as to 9-29-2015 order, including
further amendment of section, transmitted to OAL 12-15-2015 and filed
1-27-2016; amendments effective 1/27/2016 pursuant to Government Code section
11343.4(b)(3)
(Register
2016, No. 5).
4. Amendment of subsection (c)(6) filed
1-27-2020; operative 4/1/2020 (Register
2020, No. 5).
5. Amendment of section heading, section
and NOTE filed 9-17-2024; operative
9/17/2024
pursuant to Government Code section 11343.4(b)(3) (Register
2024, No. 38).
